VSTs

Phase 2Biologic

CCatherine Bollard

VSTs is one of 2 biologic programs targeting Solid Organ Transplant. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid Organ TransplantActive, not recruiting

Solid Organ TransplantPhase 2

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Solid Organ Transplant

#DrugCompanyPhaseTrials

Prograf

VVeloxis Pharmaceuticals

Approved

1 2

VSTs

CCatherine Bollard

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2032

Phase 2Active, not recruiting

Solid Organ Transplant

NCT04331275

Clinical

Trials by Indication[1]

T Cell1 trial

Allogeneic Virus-specific T Cell Lines (VSTs)

Completed·CCatherine Bollard·Phase 1·NCT02510417·31 enrolled

Solid Organ Transplant1 trial

Viral Specific T-cells (VSTs) for Treatment of Viral Infections After Solid Organ Transplant

Active, not recruiting·CChildren's Hospital Medical Center, Cincinnati·Phase 2·NCT04331275·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for VSTs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VSTs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VSTs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Catherine Bollard company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: CCatherine Bollard

VSTs

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2032

Trials by Indication[1]

T Cell1 trial

Solid Organ Transplant1 trial

References

Drug Info

Quick Facts

Related News